Key Findings
- Among 10,833 ER+/HER2- breast cancers profiled by Caris, licensing complex and IFNγ transcriptional profiles stratified endocrine therapy ± CDK4/6 inhibitor outcomes and may provide additional predictive value in TP53 wild-type disease.
- Collectively, these studies demonstrate how integrated genomic, transcriptomic, and immune profiling can identify biologically distinct breast cancer subgroups, refine therapeutic stratification, and uncover potential biomarkers of treatment response and resistance across metastatic, hormone receptor–positive, and triple-negative disease.